Reported Severe Hypersensitivity Reactions after Intravenous Iron Administration in the European Economic Area (EEA) Before and After Implementation of Risk Minimization Measures

Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside‐1000 (Monofer ® ) versus ferric carboxy‐maltose (Ferinject ® ). A single center, cohort study

(2018) Midas B. Mulder et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017

(2018) Birgit Ehlken et al.   DRUG SAFETY

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2017) Theo Vos et al.   LANCET

Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs

(2017) Ankur Arora et al.   Therapeutics and Clinical Risk Management

Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products

(2015) Cunlin Wang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Weber Effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): Analysis of Sixty-Two Drugs Approved from 2006 to 2010

(2014) Keith B. Hoffman et al.   DRUG SAFETY

Trends of reporting of ‘serious’vs. ‘non-serious’ adverse drug reactions over time: a study in the French PharmacoVigilance Database

(2012) Guillaume Moulis et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Foreword

(2012)   Kidney International Supplements

Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America

(2011) George Bailie et al.   ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH

The Case-Population Study Design

(2011) Hélène Théophile et al.   DRUG SAFETY